Oncotarget

Reviews:

Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies

Etienne Giroux Leprieur _, David M. Jablons and Biao He

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:14680-14691. https://doi.org/10.18632/oncotarget.24411

Metrics: PDF 1473 views  |   HTML 3295 views  |   ?  


Abstract

Etienne Giroux Leprieur1,2, David M. Jablons3 and Biao He3

1Department of Respiratory Diseases and Thoracic Oncology, APHP - Ambroise Paré Hospital, Boulogne-Billancourt, France

2EA 4340 BCOH, UVSQ, Paris-Saclay University, Boulogne-Billancourt, France

3Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA

Correspondence to:

Etienne Giroux Leprieur, email: [email protected]

Keywords: Sonic Hedgehog; lung cancer; mesothelioma; cancer stem cell; chemoresistance

Received: November 11, 2017    Accepted: January 25, 2018    Epub: February 06, 2018    Published: March 06, 2018

ABSTRACT

The Sonic Hedgehog (Shh) pathway is physiologically involved during embryogenesis, but is also activated in several diseases, including solid cancers. Previous studies have demonstrated that the Shh pathway is involved in oncogenesis, tumor progression and chemoresistance in lung cancer and mesothelioma. The Shh pathway is also closely associated with epithelial-mesenchymal transition and cancer stem cells. Recent findings have revealed that a small proportion of lung cancer cells expressed an abnormal full-length Shh protein, associated with cancer stem cell features. In this paper, we review the role of the Shh pathway in thoracic cancers (small cell lung cancer, non-small cell lung cancer, and mesothelioma) and discuss the new perspectives of cancer research highlighted by the recent data of the literature.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24411